Item Type | Name |
Concept
|
Protein-Tyrosine Kinases
|
Concept
|
Protein Kinases
|
Concept
|
Mitogen-Activated Protein Kinases
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p21
|
Concept
|
Phosphotransferases
|
Concept
|
Protein Kinase C
|
Concept
|
Class I Phosphatidylinositol 3-Kinases
|
Concept
|
TOR Serine-Threonine Kinases
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p15
|
Concept
|
Cyclin-Dependent Kinases
|
Concept
|
Phosphatidylinositol 3-Kinases
|
Concept
|
MAP Kinase Signaling System
|
Concept
|
Janus Kinase 2
|
Concept
|
Ribosomal Protein S6 Kinases, 70-kDa
|
Concept
|
Protein Kinase C-alpha
|
Concept
|
Protein Kinase Inhibitors
|
Academic Article
|
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
|
Academic Article
|
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
|
Academic Article
|
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
|
Academic Article
|
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.
|
Academic Article
|
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
|
Academic Article
|
Terminal ballistics of kinase inhibitors: there are no magic bullets.
|
Academic Article
|
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
|
Academic Article
|
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.
|
Academic Article
|
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
|
Academic Article
|
Genome-wide identification of genetic determinants for the cytotoxicity of perifosine.
|
Academic Article
|
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
|
Academic Article
|
EGFR pharmacogenomics: the story continues to mutate and evolve.
|
Academic Article
|
A survey of the population genetic variation in the human kinome.
|
Academic Article
|
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
|
Academic Article
|
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
Academic Article
|
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.
|
Academic Article
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
Academic Article
|
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
|
Academic Article
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
Academic Article
|
Rapamycin: something old, something new, sometimes borrowed and now renewed.
|
Academic Article
|
Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors.
|
Academic Article
|
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
|
Academic Article
|
Playing Russian roulette with tyrosine kinase inhibitors.
|
Academic Article
|
A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection.
|
Academic Article
|
Preventing adverse drug-drug interactions: a need for improved data and logistics.
|
Academic Article
|
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
|
Academic Article
|
Vemurafenib oral bioavailability: an insoluble problem.
|
Academic Article
|
Obviating the Need for Serial Biopsies Through Random Assignment.
|
Academic Article
|
A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC).
|
Academic Article
|
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
|
Academic Article
|
Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.
|
Academic Article
|
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
|
Academic Article
|
Influence of N-acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib.
|
Academic Article
|
Subcutaneous Atezolizumab: A Jab Without a Benefit.
|
Academic Article
|
Lorlatinib Exposed: A Far From Optimal Dose.
|
Academic Article
|
The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force.
|